Small Pharma Inc. (DMTTF) Stock
Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Small Pharma Inc.
Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder. Specifically, its compound SPL026 is currently in Phase IIA clinical trials for MDD treatment. The company's preclinical pipeline also includes SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. Founded in 2015, Small Pharma Inc. is headquartered in London, United Kingdom.
Small Pharma Inc. is headquartered in GB.
Small Pharma Inc. (DMTTF) stock trades at $0.11 with a market capitalization of $37.51M. The stock is valued at a price-to-earnings (P/E) ratio of -2.20, price-to-book of 2.93, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.05 and $0.19, and currently trades 42.1% below its 52-week high.
On profitability, Small Pharma Inc. generates a return on equity (ROE) of -78.43%, return on capital employed of -141.33%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.smallpharma.com